Globe Newswire08.29.18
Lexington Biosciences Inc., a development-stage medical device company, has been issued U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device.
“The news is a big deal for Lexington,” CEO Eric Willis said. “The U.S. Patent Office and our legal team did an extraordinary job in arriving at this approval so quickly. The fact that all key claims were reviewed and approved without significant amendment speaks volumes to the veracity of our research and the clearly defined parameters of the operating methodology. We also have numerous patents pending on individual aspects of the science, both domestically and overseas, but this particular patent approval should pave the way for subsequent approvals in other global jurisdictions.”
HeartSentry was designed by Lexington’s lead researcher, Chief Scientific Advisor Jonathan S. Maltz, Ph.D., as a diagnostic device that provides a new approach to non-invasive measurement and monitoring of cardiovascular health. The device assesses the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The company designed HeartSentry to be highly portable, accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium (the innermost lining of the cardiovascular system). Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.
The HeartSentry core technology was developed at the Lawrence Berkeley National Laboratory over a 15-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Lexington Biosciences hopes to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
“The news is a big deal for Lexington,” CEO Eric Willis said. “The U.S. Patent Office and our legal team did an extraordinary job in arriving at this approval so quickly. The fact that all key claims were reviewed and approved without significant amendment speaks volumes to the veracity of our research and the clearly defined parameters of the operating methodology. We also have numerous patents pending on individual aspects of the science, both domestically and overseas, but this particular patent approval should pave the way for subsequent approvals in other global jurisdictions.”
HeartSentry was designed by Lexington’s lead researcher, Chief Scientific Advisor Jonathan S. Maltz, Ph.D., as a diagnostic device that provides a new approach to non-invasive measurement and monitoring of cardiovascular health. The device assesses the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The company designed HeartSentry to be highly portable, accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium (the innermost lining of the cardiovascular system). Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.
The HeartSentry core technology was developed at the Lawrence Berkeley National Laboratory over a 15-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Lexington Biosciences hopes to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.